We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
The current LSRM market cap is 25.38M. The company's latest EPS is USD -0.4485 and P/E is -0.94.
| Year End September 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Revenue | 559k | 0 | 0 | 0 | 0 |
| Operating Income | -28.98M | -36.19M | -36.06M | -31.48M | -26.35M |
| Net Income | -30.28M | -36.71M | -37.63M | -32.37M | -27.58M |
| Year End September 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Total Assets | 40.54M | 75.87M | 50.52M | 30.53M | 26.99M |
| Total Liabilities | 20.81M | 19.34M | 18.36M | 17.31M | 14.13M |
| Total Equity | 19.73M | 56.53M | 32.16M | 13.22M | 12.87M |
| Year End September 29 2024 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| USD (US$) | USD (US$) | USD (US$) | USD (US$) | USD (US$) | |
| Operating | -15.28M | -18.79M | -18.24M | -22.85M | -18.81M |
| Investing | -2.7M | -15.19M | 5.49M | -372k | -108k |
| Financing | 25.04M | 54.52M | -638k | 4.69M | 19.51M |
| Market Cap | 25.38M |
| Price to Earnings Ratio | -0.94 |
| Price to Sales Ratio | 0 |
| Price to Cash Ratio | 20.49 |
| Price to Book Ratio | 2.01 |
| Dividend Yield | - |
| Shares Outstanding | 61.49M |
| Average Volume (1 week) | 0 |
| Average Volume (1 Month) | 0 |
| 52 Week Change | - |
| 52 Week High | - |
| 52 Week Low | - |
| Spread (Intraday) | 0.03 (6.83%) |
| Company Name | Cel-Sci Corp. |
| Address |
7700 e arapahoe rd centennial, colorado 80112 1268 |
| Website | https://www.cel-sci.com |
| Industry | biological pds,ex diagnstics (2836) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
